Spina bifida epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
 
(3 intermediate revisions by the same user not shown)
Line 4: Line 4:
{{CMG}}; {{AE}}{{MMJ}}  
{{CMG}}; {{AE}}{{MMJ}}  
==Overview==
==Overview==
 
The incidence of spina bifida is approximately 3.5 per 10,000 live births per year in the U.S. The prevalence of spina bifida is approximately 187 to 890 per 100,000 live births. Before 1960, the case-mortality rate of all forms of spina bifida was 90% to 88%. Now the mortality rate is approximately is 10.1%. The overall [[Ventriculoperitoneal shunt|ventriculoperitoneal]] shunt requirement rate is 33.8%. The [[paraplegia]] rate is 30.7%. The [[neurogenic bladder]] rate is 51.6%. The [[infection]] rate is 6.4% after the surgical procedure. Spina bifida is more commonly observed among preterm newborns. Spina bifida usually affects individuals of the Malays and Chinese and Indians race. Female are more commonly affected by  than male. The male\male+female ratio is approximately 42%.
*
===Age===
*Spina bifida is more commonly observed among preterm newborns.<ref name="pmid4898641">{{cite journal |vauthors=Bannur BB, Purandare GM |title=Microbial production of L-lysine |journal=Hindustan Antibiot Bull |volume=11 |issue=3 |pages=191–205 |date=February 1969 |pmid=4898641 |doi= |url=}}</ref>
===Gender===
*Female newborns are more commonly affected with spina bifida than male newborns.<ref name="pmid3738390">{{cite journal |vauthors=Doutre MS, Beylot C, Busquet M, Barberis C, Fauchier JM, Lecastereyres D, Beylot J |title=[Familial scleroderma of the Thibierge-Weissenbach type] |language=French |journal=Rev Rhum Mal Osteoartic |volume=53 |issue=4 |pages=290–1 |date=April 1986 |pmid=3738390 |doi= |url=}}</ref>
===Race===
 
*Spina bifida usually affects individuals of the Malays and Chinese and Indians race.<ref name="pmid5684468">{{cite journal |vauthors=Csaba G, Körösi J |title=A new antitumour agent: phenazathionium-mustard salt |journal=Neoplasma |volume=15 |issue=4 |pages=443–5 |date=1968 |pmid=5684468 |doi= |url=}}</ref>
 
 
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
Line 23: Line 10:


===Prevalence===
===Prevalence===
The prevalence of spina bifida is approximately 187 to 890 per 100,000 live births.<ref name="pmid5684468" />
The prevalence of spina bifida is approximately 187 to 890 per 100,000 live births.<ref name="pmid5684468">{{cite journal |vauthors=Csaba G, Körösi J |title=A new antitumour agent: phenazathionium-mustard salt |journal=Neoplasma |volume=15 |issue=4 |pages=443–5 |date=1968 |pmid=5684468 |doi= |url=}}</ref>


===Case-fatality rate/Mortality rate===
===Case-fatality rate/Mortality rate===
Line 36: Line 23:


===Age===
===Age===
*Patients of all age groups may develop [disease name].
Spina bifida is more commonly observed among preterm newborns.<ref name="pmid4898641">{{cite journal |vauthors=Bannur BB, Purandare GM |title=Microbial production of L-lysine |journal=Hindustan Antibiot Bull |volume=11 |issue=3 |pages=191–205 |date=February 1969 |pmid=4898641 |doi= |url=}}</ref>
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
*[Chronic disease name] is usually first diagnosed among [age group].
*[Acute disease name] commonly affects [age group].


===Race===
===Race===
*There is no racial predilection to [disease name].
*Spina bifida usually affects individuals of the Malays and Chinese and Indians race.<ref name="pmid5684468" />
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
===Gender===
===Gender===
*[Disease name] affects men and women equally.
*Female are more commonly affected by than male. The male\male+female ratio is approximately 42%.<ref name="pmid5045772">{{cite journal |vauthors=Bass SW, Triolo AJ, Coon JM |title=Effect of DDT on the toxicity and metabolism of parathion in mice |journal=Toxicol. Appl. Pharmacol. |volume=22 |issue=4 |pages=684–93 |date=August 1972 |pmid=5045772 |doi= |url=}}</ref>
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
 
===Region===
*The majority of [disease name] cases are reported in [geographical region].
 
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
 
===Developed Countries===
 
===Developing Countries===


==References==
==References==

Latest revision as of 19:09, 28 January 2019

Spina bifida Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Spina Bifida from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electroencephalogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Spina bifida epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Spina bifida epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Spina bifida epidemiology and demographics

CDC on Spina bifida epidemiology and demographics

Spina bifida epidemiology and demographics in the news

Blogs on Spina bifida epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Spina bifida epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

The incidence of spina bifida is approximately 3.5 per 10,000 live births per year in the U.S. The prevalence of spina bifida is approximately 187 to 890 per 100,000 live births. Before 1960, the case-mortality rate of all forms of spina bifida was 90% to 88%. Now the mortality rate is approximately is 10.1%. The overall ventriculoperitoneal shunt requirement rate is 33.8%. The paraplegia rate is 30.7%. The neurogenic bladder rate is 51.6%. The infection rate is 6.4% after the surgical procedure. Spina bifida is more commonly observed among preterm newborns. Spina bifida usually affects individuals of the Malays and Chinese and Indians race. Female are more commonly affected by than male. The male\male+female ratio is approximately 42%.

Epidemiology and Demographics

Incidence

The incidence of spina bifida is approximately 3.5 per 10,000 live births per year in the U.S.[1][2]

Prevalence

The prevalence of spina bifida is approximately 187 to 890 per 100,000 live births.[3]

Case-fatality rate/Mortality rate

  • Before 1960, the case-mortality rate of all forms of spina bifida was 90% to 88%.[4]
  • In all patients with neural tube defects including spina bifida:[5]

Age

Spina bifida is more commonly observed among preterm newborns.[6]

Race

  • Spina bifida usually affects individuals of the Malays and Chinese and Indians race.[3]

Gender

  • Female are more commonly affected by than male. The male\male+female ratio is approximately 42%.[1]

References

  1. 1.0 1.1 Bass SW, Triolo AJ, Coon JM (August 1972). "Effect of DDT on the toxicity and metabolism of parathion in mice". Toxicol. Appl. Pharmacol. 22 (4): 684–93. PMID 5045772.
  2. Parker SE, Mai CT, Canfield MA, Rickard R, Wang Y, Meyer RE, Anderson P, Mason CA, Collins JS, Kirby RS, Correa A (December 2010). "Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006". Birth Defects Res. Part A Clin. Mol. Teratol. 88 (12): 1008–16. doi:10.1002/bdra.20735. PMID 20878909.
  3. 3.0 3.1 Csaba G, Körösi J (1968). "A new antitumour agent: phenazathionium-mustard salt". Neoplasma. 15 (4): 443–5. PMID 5684468.
  4. Lorber J (June 1971). "Results of treatment of myelomeningocele. An analysis of 524 unselected cases, with special reference to possible selection for treatment". Dev Med Child Neurol. 13 (3): 279–303. PMID 4937369.
  5. Carreras y Matas M (1971). "[Strabismic sensorial perversions as a cause of secondary vertical deviation]". Rev Esp Otoneurooftalmol Neurocir (in Spanish; Castilian). 29 (172): 361–3. PMID 5141554.
  6. Bannur BB, Purandare GM (February 1969). "Microbial production of L-lysine". Hindustan Antibiot Bull. 11 (3): 191–205. PMID 4898641.

Template:WH Template:WS